

FORM PTO1449 (REV. 8-83)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE						ATTY. DOCKET NO.		SERIAL NO.		
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>								APPLICANT Edward T. Wei				
								FILED September 11, 2003		GROUP		
		U.S. PATENT DOCUMENTS										
EXAMINER INITIAL		DOCUMENT NUMBER				DATE	NAME		Class	Sub Class	Filing Date	
KS	A1	4	0	7	0	4	9	6	1/24/78	Rowsell and Spring		
KS	A2	5	5	8	2	3	3	0	12/28/94	Iba		
	A3											
	A4											
	A5											
	A6											
	A7											
	A8											
	A9											
	A10											
FOREIGN PATENT DOCUMENTS												
		DOCUMENT NUMBER				DATE	COUNTRY		Class	Sub Class	Trans? (Yes/No)	
	B1											
	B2											
	B3											
	B4											
	B5											
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, etc.)												
KS	C1	Code of Federal Regulations, Section 21 Part 349, Ch. 1(4-1-01 Edition). pg. 270 to 275. Ophthalmic Drug Products for Over-the Counter Human Use.										
KS	C2	G. Hecht, Ophthalmic Solutions, Chapt 43, pg. 821-835, in "Remington, the Science and Practice of Pharmacy," Alfonso R. Gennaro, Editor. 20th ed. Baltimore, Md.: Lippincott Williams & Wilkins, 2000.										
KS	C3	H.R. Watson, R. Hems, D.G. Rowsell and D.J. Spring. New Compounds with the Menthol Cooling Effect. Journal of the Society of Cosmetic Chemistry. 29: 185-200, 1978.										
EXAMINER <i>Kontinen, Shaff</i>				DATE CONSIDERED <i>03/19/07</i>								
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												